目的 探討心悅膠囊聯(lián)合非洛地平治療冠心病心絞痛的療效。方法 選取2019年6月—2020年6月在河南中醫(yī)藥大學(xué)第一附屬醫(yī)院進行治療的66例冠心病心絞痛患者，根據(jù)住院的先后順序分為對照組和治療組，每組各33例。對照組口服非洛地平緩釋片，5 mg次，1次/d。治療組在對照組治療基礎(chǔ)上口服心悅膠囊，0.6 g/次，3次/d。兩組患者均治療12周。觀察兩組的臨床療效，比較兩組相關(guān)評分、心功能指標和血清學(xué)指標的變化情況。結(jié)果 經(jīng)治療，治療組心絞痛癥狀療效總有效率是96.97%，顯著高于對照組的81.82%（P<0.05）；治療組心電圖療效是96.97%，顯著高于對照組的84.85%（P<0.05）。經(jīng)治療，兩組西雅圖心絞痛量表（SAQ）評分、WHOQOL-BREF評分、自我效能感量表（GSES）評分均較治療前顯著升高，但GRACE評分顯著降低（P<0.05）；治療后，治療組相關(guān)量表評分改善優(yōu)于對照組（P<0.05）。經(jīng)治療，兩組心臟指數(shù)（CI）、E峰流速/A峰流速（E/A）、心排血量（CO）均顯著升高（P<0.05），且治療后治療組心功能改善更明顯（P<0.05）。經(jīng)治療，兩組血清組織內(nèi)轉(zhuǎn)化生長因子β結(jié)合蛋白2（LTBP2）、白三烯B4（LTB4）、白細胞介素-18（IL-18）、心肌營養(yǎng)素1（CT-1）、中性粒細胞明膠酶相關(guān)載脂蛋白（NGAL）水平均顯著降低（P<0.05）；且治療后治療組患者血清學(xué)指標低于對照組（P<0.05）。結(jié)論 心悅膠囊聯(lián)合非洛地平治療冠心病心絞痛可有效改善患者癥狀，促進患者心功能及血清細胞因子水平的改善，有利于提高患者生存質(zhì)量，有良好的臨床應(yīng)用價值。

Objective To explore the effect of Xinyue Capsules combined with felodipine in treatment of coronary heart disease angina pectoris.Methods A total of 66 patients with coronary heart disease angina pectoris who were treated in the First Affiliated Hospital of Henan University of CM from June 2019 to June 2020 were selected and divided into control group and treatment group according to the order of hospitalization, with 33 patients in each group. Patients in the control group were po administered with Felodipine Sustained Release Tablets, 5 mg/time, once daily. Patients in the treatment group were po administered with Xinyue Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scores, cardiac function indexes and serological indexes were compared between the two groups.Results After treatment, the total effective rate of angina symptom in treatment group was 96.97%, which was significantly higher than that of control group (81.82%,P<0.05). The ECG efficacy of the treatment group was 96.97%, which was significantly higher than that of the control group (84.85%,P<0.05). After treatment, Seattle Angina Scale (SAQ) score, WHOQOL-BREF score and self-efficacy scale (GSES) score were significantly increased, but GRACE score was significantly decreased (P<0.05). After treatment, the improvement of related scale scores in treatment group was better than that in control group After treatment, cardiac index (CI), peak velocity of E/A (E/A), and cardiac output (CO) were significantly increased in both groups (P<0.05), and cardiac function was improved more significantly in the treatment group after treatment (P<0.05). After treatment, the levels of transforming growth factor β-binding protein 2 (LTBP2), leukotriene B4 (LTB4), interleukin-18 (IL-18), cardiomyutrient 1 (CT-1), and neutrophil gelatase-associated apolipoprotein (NGAL) in serum were significantly decreased in both groups (P<0.05). After treatment, the serum indexes in the treatment group were lower than those in the control group (P<0.05).Conclusion Xinyue Capsules combined with felodipine can effectively improve the symptoms of patients in treatment of coronary heart disease angina pectoris, and can promote the improvement of cardiac function and serum cytokine levels, and is conducive to improve the life quality of patients, which has a good clinical application value.

R972

河南省中醫(yī)藥科學(xué)研究專項課題（2016ZY3003）